Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a quicker chemo beat breast cancer better?

NCT ID NCT05728268

Disease control Sponsor: Shantou Central Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether giving chemotherapy on a faster schedule (called dose-dense) works better for women with a common type of breast cancer (HR+/HER2-) that grows quickly (high Ki67). About 64 women will receive the faster chemo before surgery to see if it reduces the amount of cancer left behind. The goal is to find out who benefits most from this approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dose-dense nab-paclitaxel followed by EC (a type of chemotherapy given on a faster schedule)
What this could lead to
If successful, this could show that a faster chemotherapy schedule helps shrink tumors more effectively in certain breast cancer patients, potentially lowering recurrence risk.
What could go wrong
This is a small phase 2 trial with only 64 participants, so results may not apply to all patients. The faster schedule may also cause more side effects like fatigue or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 64 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2021

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Females with age of 18 to 70 years old. * Newly diagnosed breast cancer patients. * Planned neoadjuvant chemotherapy. * Hormone receptor status: Estrogen receptor (ER)-positive or Progesterone Receptor (PR)- positive. * HER2/neu-negative. * Ki67≥30%. * Clinical stage IIB-IIIC. * Informed consent form understood and signed. * Patient agrees to all follow-up visits. * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. * Women of childbearing potential must have a negative serum pregnancy test. Exclusion Criteria: * Metastatic disease * Pregnancy. * Nursing mothers. * Active or uncontrolled infection. * Presence of another malignancies. * Granulocyte count \< 1.5\*10\^9/L. * Platelet count \< 100\*10\^9/L. * Hemoglobin \< 90g/L. * Serum Creatinine more than 1.5 upper limit. * AST and ALT more than 2.5 upper limit. * LVEF\< 50%.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shantou Central Hospital

    RECRUITING

    Shantou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.